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Abstract
Resection is the only curative treatment for liver metastasis of colorectal cancers. Despite the
supreme regenerative potential of the liver, major hepatectomy sometimes leads to liver failure,
and the limitation of resectable liver volumes makes advanced tumors inoperable. This study was
attempted to promote liver regeneration using hepatocyte growth factor (HGF) gene transfection
by venous-administered adenovirus and to improve the survival of rats after massive hepatec-
tomy. The adenovirus that encodes HGF was administered to rats before 85%-hepatectomy. The
administration of HGF gene improved the survival of rats after massive hepatectomy, while the ad-
ministration of control adenovirus deteriorated their survival. Gene transfection of HGF showed
up-regulation of serum HGF, stimulation of hepatocellular proliferation and rapid liver regenera-
tion. Moreover, HGF administration reduced apoptosis of hepatocytes. The administration of HGF
gene prevented liver dysfunction after major hepatectomy and may be a new assist for surgery.
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esection is the mainstay of treatments for 
malignant liver tumors,  which depends on the 
extent of the disease and underlying liver function. 
But extended hepatectomy has been associated with a 
high risk of complications,  especially postoperative 
liver failure.  Preoperative embolism of the portal 
vein has been undertaken to increase the remnant 
liver volumes and reduce complications [1,  2].  Liver 
transplantation has also been performed for nonre-
sectable tumors,  but the procedure has many limita-
tions [3].  The use of a bio-artiﬁ cial liver as a bridge 
is one promising experimental approach.  And the 
promotion of liver regeneration using hepatocyte 
growth factor (HGF) or other growth factors is 
another approach that has been tested in several 
experimental models.
　　HGF is a well-known growth factor with mito-
genic,  motogenic,  and morphogenic activities for a 
wide variety of cells and has proven to be the most 
potent stimulator of cellular growth and DNA syn-
thesis of hepatocytes in vitro and in vivo [4ﾝ7].  HGF 
is also thought to initiate hepatic regeneration after 
hepatectomy,  to protect cells against acute hepatic 
injury,  and to have an anti-apoptotic eﬀ ect [8ﾝ10]. 
Due to the rapid clearance of HGF,  frequent admin-
istration is necessary to maintain eﬀ ective serum lev-
els.  Thus,  gene transfection has recently been exam-
ined to achieve consistent production of HGF.  The 
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gene transfection of HGF by adenoviral vector or ret-
roviral vector has already been proved to stimulate 
hepatocyte regeneration after hepatectomy and to 
protect against liver failure [10ﾝ12].
　　In this study,  we examined whether HGF gene 
transfection by adenoviral vector could support liver 
regeneration and survival of rats after massive hepa-
tectomy.
Materials and Methods
　　Animal model.　 The 7-week old Sprague 
Dawley rats were purchased from Charles River 
Japan Inc.  (Yokohama,  Japan) and kept at the Animal 
Center for Medical Research,  Okayama University. 
Under ether anesthesia,  the median,  left,  right 
lobes,  and caudate process of the caudate lobes were 
resected as an 85ｵ-partial hepatectomy model.  A 
surgeon was blinded regarding the previous treat-
ments rats had received before the surgical proce-
dure.  All experiments were carried out in accor-
dance with the guidelines for Animal Experiments at 
Okayama University.
　　Viral production.　 E1-deleted recombinant 
adenoviral vector,  which encodes rat HGF cDNA 
under chicken beta-actin promoter (Adex1CA rat 
HGF),  was supplied by the RIKEN Bio resource 
Center (Tsukuba,  Japan).  Large-scale Adex1CA rat 
HGF preparation on 293 cells and puriﬁ cation by 
two-step ultra-centrifugation on cesium chloride gra-
dients were carried out.  Serial dilutions of 
Adex1CA rat HGF were plated on 293 cells,  and the 
titer was evaluated with a plaque assay.  The E1/
E3-deleted AdLacZ virus,  which prepared in the 
same manner,  was used as a negative control.  Whole 
viral experiments were admitted by committee for 
recombinant DNA experiments at Okayama 
University and were carried out in P2 facilities in 
the Department of Radiation Research,  Shikata 
Laboratory,  Advanced Science Research Center, 
Okayama University.
　　Viral administration.　 A 1 × 109 pfu (plaque 
forming units) of Adex1CA rat HGF or AdLacZ 
were administered to rat with 100 μl of PBS via 
penile vein (referred to as the HGF and LacZ 
groups,  respectively).  Control rats were adminis-
tered 100 μl of PBS alone (referred to as the 
Control group).  After 48 h,  the massive hepatectomy 
was performed because adenoviral HGF expression 
started from 12 h and reached its peak at 48 h after 
viral administration with previous examination in 
vitro (data not shown).
　　Liver regeneration.　 Rats were sacriﬁ ced at 
24,  48,  72,  and 168 h following hepatectomy,  and 
liver weight was evaluated.  Based on the resected 
liver weights at the time of surgery and when sacri-
ﬁ ced,  the ｵ liver weight was calculated as follows. 
ｵ liver weight (ｵ) ＝{Actual liver weight (g) × 0.85 
/ the resected liver weight (g)}× 100 (ｵ).
　　Measurement of serum HGF.　 Serum HGF 
was quantiﬁ ed with enzyme-linked immunosorbent 
assay (ELISA) before and at 1,  2,  6,  12,  24,  48, 
72,  and 168 h following the hepatectomy.  The proce-
dures were carried out according to the manufac-
turer’s instructions using anti-rat HGF monoclonal 
antibody Kit (Institute of Immunology,  Tokyo, 
Japan).
　　Evaluation of liver function.　 Blood samples 
were analyzed for total protein (TP),  albumin, 
aspartate aminotransferase (AST),  alanine amino-
transferase (ALT),  total bilirubin (T-Bil),  direct bil-
irubin (D-Bil),  ALP,  γ-GTP,  and ammonia.
　　Proliferative activity of hepatocytes.　 Rats 
were intraperitoneally injected with 0.5 mg/body of 
5-bromo-2’-deoxyuridene (BrdU) (Sigma-Aldrich-
Japan,  Tokyo,  Japan) diluted in PBS at a concentra-
tion of 2 mg/ml and sacriﬁ ced 1 h after BrdU admin-
istration.  The liver was ﬁ xed in 4ｵ phosphate-buﬀ -
ered formaldehyde.  Paraﬃ  n-embedded liver sections 
were immunostained with monoclonal antibody of 
BrdU conjugated with peroxidase.  The proliferation 
index was determined by counting stained nucleus in 
3 diﬀ erent sections of the same rats.
　　Evaluation of apoptosis.　 Apoptotic cells on 
liver sections were stained with the terminal-deoxyri-
bosyl-transferase-mediated deoxyuridine nick-end 
labeling (TUNEL) methods and detected.  A commer-
cially available kit of reagents for the TUNEL meth-
ods (ApopTag ; Oncor ; Gautherburg,  MD,  USA) 
was used according to the manufacturer’s instruction. 
The apoptotic index was determined by counting 
stained nucleus in three diﬀ erent liver sections of the 
same rats.
　　Statistical analysis.　 Survival of rats was 
determined by the Kaplan-Meier method and com-
pared by the Log-rank test.  The diﬀ erence in experi-
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mental parameters and proliferation index among the 
treatment groups was analyzed using the one-way 
ANOVA test.  For all tests,  p ＜ 0.05 was considered 
signiﬁ cant.
Results
　　Establishment of animal models.　 A 70ｵ 
partial hepatectomy model of rats has been estab-
lished with the removal of median lobe and left lat-
eral lobe [13],  and additional resection of right lat-
eral lobe results in 85 ± 3ｵ partial hepatectomy, 
based on our preliminary study (n ＝ 6).  With this 
model,  66ｵ rats of the Control group died within 1 
week of hepatectomy (Fig.  1).  Dead rats underwent 
laparotomy and were found to have small and ﬁ rm 
livers and ascites in most cases ; they were therefore 
considered to have died of liver failure.  Additional 
resection of the upper half of the caudal lobe created 
a 90ｵ-resection model,  but all rats died within 3 
days (data not shown).  We used an 85ｵ-partial hepa-
tectomy procedure as a massive hepatectomy model 
for further examination.
　　Transfectional rate of hepatocytes.　 A 
1 × 109 pfu of AdLacZ was administered intrave-
nously,  and liver tissue was stained with X-gal at 
48 h after viral administration.  Nearly 80ｵ of hepa-
tocytes showed expression (data not shown).
　　Survival of rats.　 In the Control group (n ＝ 18), 
which was administered only PBS,  66ｵ of rats died 
within a week (Fig.  1).  But all rats that were admin-
istered AdLacZ (n ＝ 6) died within 4 days.  In the 
HGF group (n ＝ 18),  72ｵ of rats survived for a 
week and the survival rate was signiﬁ cantly higher 
than the Control and LacZ groups.  The deteriora-
tion of survival in the LacZ group was considered to 
due to the toxicity of adenovirus toward liver.  We 
used the HGF and Control groups for further exami-
nation,  because the aim of our study was to prove 
that the beneﬁ ts of HGF could overwhelm the toxic 
eﬀ ect of adenovirus.
　　Regeneration of liver.　 All survival rats were 
sacriﬁ ced on the 7 th day following hepatectomy,  and 
the remnant liver weight was examined.  The liver 
weights of each group were 6.6 ± 0.6 grams in the 
Control group and 7.9 ± 0.5 grams in the HGF group, 
which were 63.4ｵ and 75.5ｵ of estimated whole 
liver weight at the time of surgery,  respectively (Fig. 
2).  There was no data for the LacZ group because 
no rats in the LacZ group survived for 7 days.  To 
clarify the liver regeneration in the early stage,  rats 
in each group were sacriﬁ ced at 24,  48,  and 72 h 
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Fig. 1　　Survival curve of rats after hepatectomy in Control, 
LacZ,  and HGF groups.  The HGF group (n ＝ 18) had a 
signiﬁ cantly better survival rate than the Control group (n ＝ 18). 
On the other hand,  all rats of the LacZ group were dead within 4 
days (n ＝ 6).  ＊ : p ＜ 0.05,  ＊＊ : p ＜ 0.01.
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Fig. 2　　Liver weight after massive hepatectomy.  The estimated 
liver weight at the time of surgery is indicated as 100%,  and the 
% liver weights at each time point are shown (n ＝ 6 ; except 
n ＝ 13 for HGF group at 168 h).  Values are expressed as the 
mean ± SD.  ＊ : p ＜ 0.05,  ＊＊ : p ＜ 0.01.  # : no data at 168 h of 
the LacZ group.
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Fig. 3　　Serum HGF levels at 0,  1,  2,  6,  12,  24,  48,  72,  and 168 h following hepatectomy in Control and HGF groups (n ＝ 5).  Serum 
HGF levels were signiﬁ cantly higher in the HGF group from 0 to 24 h following the surgery.  Each point represents the mean ± SD. 
＊ : p ＜ 0.05,  ＊＊ : p ＜ 0.01.
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Fig. 4　　The serum levels of total protein,  albumin,  aspartate 
aminotransferase (AST),  alanine aminotransferase (ALT),  total bil-
irubin (T-Bil),  direct bilirubin,  γ-GTP,  and ALP were studied and 
data for ALT (A),  T-Bil (B),  and ammonia (C) are represented 
(n ＝ 6).
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following hepatectomy,  and their livers were weighed 
(n ＝ 6).  The HGF group showed signiﬁ cantly higher 
liver regeneration than the Control group from 24 to 
168 h after surgery.  The liver weight of the LacZ 
group at 72 h was 26.8ｵ and was almost the same as 
that of the Control group,  which was 27.9ｵ.
　　Expression of HGF.　 HGF was found to be 
rapidly up-regulated by the stimulation of hepatec-
tomy,  but temporally decreased between 2 and 6 h in 
both groups (Fig.  3),  and this phenomenon is consid-
ered to be due to the early consumption of HGF [6]. 
In the Control group,  HGF gradually increased again 
from 12 h and peaked at 72 h after hepatectomy.  In 
contrast,  rats of the HGF group had HGF levels 
more than twice as high at the time of surgery as 
those of the Control group and showed an earlier 
re-increase in serum HGF,  which peaked at 24 h 
after hepatectomy.  HGF levels became the same in 
both groups after 48 h following surgery.
　　Liver function after hepatectomy.　 The 
serum levels of total protein,  albumin,  AST,  ALT, 
total bilirubin,  direct bilirubin,  γ-GTP,  and ALP 
were studied.  The liver functions of both groups 
were signiﬁ cantly worse than those presurgery,  even 
at 168 h after surgery,  but there was no signiﬁ cant 
diﬀ erence between the Control and HGF groups (Fig. 
4).  The absence of diﬀ erence between these groups 
may be due to the bias of data collection,  because 
only survival rats in both groups were used for analy-
sis.
　　Proliferation and apoptosis in remnant 
liver. To clarify the mechanisms of earlier liver 
regeneration in the HGF group,  we evaluated prolif-
eration and apoptosis of the liver.  The proliferation 
rates of hepatocytes in the Control and HGF groups 
were determined by BrdU incorporation and were 
evaluated histologically (Fig.  5A,  B).  The prolifer-
ating indexes were gradually increased in both 
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Fig. 5　　Paraﬃ  n-embedded liver sections with BrdU immunostaining and TUNEL staining.  The Control (A) and HGF groups (B) at 72 h 
for BrdU staining, and the Control (C) and HGF groups (D) for TUNEL staining at 72 h (× 200).
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groups but were signiﬁ cantly higher in the HGF than 
the Control group from 24 to 72 h following massive 
hepatectomy (Table 1).  Apoptotic cells were found in 
both the Control and HGF groups (Fig.  5C,  D),  but 
the number of apoptotic cells in the HGF group 
decreased signiﬁ cantly in comparison with the 
Control group (Table 2).
Discussion
　　In an eﬀ ort to prevent liver failure after hepatec-
tomy,  various therapies have been proposed.  Portal 
vein embolization and liver transplantation have been 
adapted to nonresectable tumors,  but their indication 
is still limited.  Attempts to stimulate the prolifera-
tion of residual viable hepatocytes after hepatectomy 
have been studied [6ﾝ8,  14ﾝ17].  Hepatectomy and 
liver injury trigger hepatocyte proliferation.  The 
onset of mitosis follows 6ﾝ8 h later,  reaching a maxi-
mum 48 h after surgery [4,  17].  The priming phase 
after hepatectomy is characterized by the expression 
of immediate early genes.  Among these genes,  TNF 
and IL-6 cytokines work for priming and growth fac-
tors ; HGF and TGF-α,  control cell cycle progres-
sion [4].  Thus the previous administration of HGF 
would eﬀ ectively promote proliferation of hepato-
cytes.  It has been reported that the injection of HGF 
is able to induce liver proliferation even in normal 
rats without liver injury or hepatectomy [17].
　　This study showed that gene transfection of HGF 
stimulates liver regeneration in vivo,  which improves 
rat survival from massive hepatectomy.  The HGF 
group showed signiﬁ cantly higher liver regeneration 
than the Control group at all times.  Our data may 
still underestimate the eﬀ ects of HGF upon liver 
regeneration because only surviving rats were ana-
lyzed and dead rats might have lower liver regenera-
tion.  This problem may also account for the similar-
ity of liver function tests between the Control and 
HGF groups.  With previous in vitro examinations, 
the expression of HGF delivered by adenoviral vec-
tors has been started 12 h after viral administration 
and has reached a peak at 48 h ; we therefore admin-
istered adenovirus 48 h proceeding hepatectomy.  The 
HGF group had HGF levels more than twice as high 
the time of surgery than the Control group,  and 
overexpression of HGF at the point of hepatectomy 
may promote early proliferation of hepatocytes and 
improve rat survival.  We found no signiﬁ cant diﬀ er-
ence in serum HGF levels between surviving rats and 
dead ones in the HGF group at the preoperative time 
point.  Because the overexpression of HGF was 
shown in all rats in the HGF group,  the gene trans-
fection rate may not explain the nonsurvival rats in 
the HGF group.
　　In our model,  the single injection of adenoviral 
HGF maintained higher serum levels of HGF for at 
least 3 days ; virus was administered 48 h preceding 
surgery,  and HGF was up-regulated until 24 h after 
hepatectomy.  The previous paper suggested that 
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Table 2　　Apoptotic index
Post operative time (hour) 1　　 24 　 48 　 72
Control group (%) 2.6±1.5 1.9±0.1 1.5±0.1 2.8±0.2　
HGF group (%) 1.7±0.2 n.s. 1.1±0.3＊＊ 0.5±0.2＊＊ 1.2±0.4＊＊
Apoptotic index of hepatocytes after massive hepatectomy in the Control and HGF groups (n ＝ 6).
n.s. : not signiﬁ cant,  ＊＊ : p ＜ 0.01.
Table 1　　Proliferation index
Post operative time (hour) 1  　 24 　 48 　 72　
Control group (%) 1.5 ± 0.2 3.3 ± 0.2 7.4 ± 0.2 28.4 ± 2.7
HGF group (%) 1.7 ± 0.3 n.s. 6.0 ± 0.8＊＊ 8.5 ± 1.6＊ 36.8 ± 3.8＊＊
Proliferation index were determined by BrdU labeling of nucleus after massive hepatectomy in the Control and HGF groups (n ＝ 6).
n.s. : not signiﬁ cant,  ＊ : p ＜ 0.05,  ＊＊ : p ＜ 0.01.
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after partial hepatectomy,  the ﬁ rst phase from 0 to 
3 h is the consumption phase,  in which HGF 
decreases,  while the second phase at over 6 h is a 
productive phase,  in which HGF reappears [6].  In 
our model,  a sharp drop of serum HGF was seen 2 h 
after hepatectomy.  These phenomena were also 
observed in clinical patients after hepatectomy ; the 
maximum value of serum HGF was found the next 
day after surgery,  while serum interleukin-6,  the 
other early parameter of liver dysfunction,  reached 
its maximum on day 0 [18,  19].  Thus the previous 
administration of HGF gene may also be beneﬁ cial to 
clinical patients.  But the expression of genes admin-
istered by adenovirus may be diﬀ erent in vitro and in 
vivo.  The expression of HGF peaked at 48 h after 
viral administration in an in vitro study,  but serum 
HGF in the HGF group reached the highest point at 
24 h after hepatectomy,  72 h after viral administra-
tion.  These ﬁ ndings indicate that expression of HGF 
from transfected HGF may also be stimulated by 
hepatectomy.
　　The HGF group showed signiﬁ cantly higher liver 
regeneration until the 7 th day after surgery,  while 
HGF levels became almost the same as those of the 
Control group at 48 h.  Because HGF is the most 
potent stimulator of cell growth and DNA synthesis 
of hepatocytes,  higher HGF in the early phase of 
hepatectomy may promote hepatic regeneration and 
result in higher liver weight at 7 days.  The cell pro-
tection and anti-apoptotic eﬀ ects of HGF may also be 
the reason for higher liver weight.  We also showed 
that HGF has cytoprotective eﬀ ects.  The number of 
apoptotic cells in the HGF group signiﬁ cantly 
decreased in comparison with the Control group. 
The protective activity against hepatic injury has 
been demonstrated in the fulminant liver failure 
model induced by endotoxin [9].  HGF has also been 
proved to suppress caspase-3,  which is the key fac-
tor to induce apoptosis [11].
　　One of the obstacles to clinical use of adenoviral 
vector is its toxicity.  The LacZ group in this study 
showed deterioration of survival compared with the 
Control group,  though the live regeneration rate was 
the same as that of the Control group.  The adenovi-
ral infection,  even nonreplicating virus,  is known to 
have toxicity to hepatocytes because of the produc-
tion of viral proteins and induction of immunological 
reaction [20].  Because of the high aﬃ  nity of adeno-
virus to hepatocytes,  venous viral administration 
showed dominant infection into hepatocytes as well as 
hepatocellular cytotoxicity [21,  22].  There are sev-
eral previously reported alternative methods to using 
viral vectors.  There is a report that intramuscular 
induction of naked HGF plasmids by electrophoretion 
stimulates liver proliferation and functional recovery 
regeneration in cirrhotic liver following partial hepa-
tectomy [23].  The recombinant HGF protein has 
preventive eﬀ ects on liver injury,  but a large amount 
of HGF is required because of the rapid clearance of 
HGF from blood circulation [12,  24] ; the half-life 
of HGF in plasma is considered to be less than sev-
eral minutes.  The controlled release of HGF by bio-
degradable gelatin hydrogels has recently been 
reported to maintain serum HGF at suﬃ  cient levels 
[25],  but the cost of recombinant HGF could be a 
problem.  The use of helper-dependent adenoviral 
vector is another solution to reducing toxicity with-
out losing the eﬀ ectiveness of gene delivery to hepa-
tocytes and the ease of manipulating viral vectors [26, 
27].  Those vectors are completely devoid of viral 
coding sequences and are able to sustain high-level 
transgene expression with negligible chronic toxicity. 
Many experimental studies comparing these tech-
niques would be required before adapting HGF treat-
ments in clinics.
　　There have been reports that HGF inhibits the 
proliferation of tumor cell growth and that adenovi-
ral gene transduction of HGF has inhibitory eﬀ ects 
against hepatoma [28,  29].  But there also have been 
reports that HGF might be implicated in HCC 
growth and may stimulate colorectal or lung adeno-
carcinomas [30ﾝ32].  Though the eﬀ ects of HGF on 
cancer cell growth are still controversial,  the corre-
lation between HGF and tumor growth must be clari-
ﬁ ed before adapting these techniques to clinics 
because most hepatectomyies are performed for liver 
malignancies.
　　In summary,  use of a preceding gene transfection 
of HGF stimulates liver regeneration and improves 
animal survival after massive hepatectomy. 
Upregulation of HGF stimulates cell proliferation 
and suppresses apoptosis of remnant liver.  The diﬃ  -
culty of clinical use of recombinant HGF,  adenoviral 
HGF gene transfection,  could provide an alternative 
technique for clinical application to support liver 
function after hepatectomy.
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